

Corporate Office :
406, Silver Oaks Comm. Complex,
Opp. Arun Society, Paldi,
Ahmedabad-380 007. Gujarat, India.
Phone : 079-26584655
Fax : 079-26588054
CIN No. : L24231GJ2004PLC043861
E-mail : info@sakarhealthcare.com
Web : www.sakarhealthcare.com

Date: 26th October 2026

To
The Manager
Listing Compliance Department
National Stock Exchange of India Ltd.
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai-400051, India

Symbol: SAKAR

Sub: Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Presentation on the Unaudited Financial Results.

Please find attached the presentation on the Unaudited Financial Results (Consolidated and Standalone) for the quarter and half year ended September 30, 2026.

This is submitted for your information and records.

Thanking You,

Yours faithfully,

FOR, SAKAR HEALTHCARE LIMITED

BHARATKUMAR SUKHLAL SONI Digitally signed by BHARATKUMAR SUKHLAL SONI
Date: 2026.10.26 14:01:51 +05'30'

**BHARAT SONI
COMPANY SECRETARY AND
COMPLIANCE OFFICER**

SAKAR HEALTHCARE LIMITED

Investor Presentation | Q2 & H1FY27



This presentation and the accompanying slides (the “Presentation”), which have been prepared by **Sakar Healthcare Limited** (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.

Certain matters discussed in this Presentation may contain statements regarding the Company’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict.

These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the company’s ability to successfully implement its strategy, the Company’s future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cash flows, the Company’s market preferences and its exposure to market risks, as well as other risks.

The Company’s actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third-party statements and projections.

Financial & Operational Performance

Q2 & H1FY27 Operational Highlights

Business momentum

- 69 oncology product contracts executed; 45 commercial discussions currently underway;
- Strengthened its global oncology presence in Q2 through portfolio expansion, wider market access across the EU, UK, Canada, APAC and LATAM, and participation in CPHI Worldwide

Tech transfer

- 33 tech transfer projects underway with 4 Partners ; 33 site variations submitted & 11 approved (stringent market-EU & UK) across 18 cytotoxic molecules.
- Accord has received 6 more product site variations approval by EMA (total now becomes 8 of 11 molecules) at our oncology site
- 3 other site variation approval received from MHRA / EMA. (for 2-partners in the UK and 1 in Germany).

Regulatory approvals

- Shared 351 dossiers globally, of which 191 have been submitted and 22 have received Marketing Authorisations.
- The approved MAs are well dispersed globally: Europe & UK-11, Latin America-6, APAC-4, Canada-1
- 36 EU MA applications, of which 16 are own filings;

Backward integration (API)

- 21 APIs developed in-house; 16 with Written Confirmation; 8 commercialised; 2 of 7 CEP applications approved, 5 currently under process
- Commercial supplies to domestic & International Markets has started from the API-integrated, EU GMP-approved oncology FDF site


General update

- Cancer coverage widened to breast, lung, prostate, stomach, head & neck, colorectal, ovary, liver, kidney, thyroid, blood, bone-marrow and lymph
- Sakar is moving towards an integrated, regulatory-driven business model, with greater value-chain integration improving supply-chain control, margin visibility and scalability.


Q2 & H1FY27 – Consolidated Financial Highlights

INR in Lakhs





Revenue



EBITDA



PAT



Q2 & H1FY27 – Consolidated Profit & Loss Statement

Particulars (INR in Lakhs)	Q2 FY27	Q2 FY26	Y-o-Y	Q1 FY27	Q-o-Q	H1FY27	H1FY26	Y-o-Y
Revenue from Operations	8,741.61	5,756.04	52%	7,297.25	20%	16,038.86	11,029.66	45%
COGS	4,573.56	3,040.64		3,458.22		8,031.78	5,935.88	
Gross Profit	4,168.05	2,715.40	53%	3,839.03	9%	8,007.08	5,093.78	57%
Gross Profit Margin (%)	48%	47%		53%		50%	46%	
Employee Expenses	976.16	834.19		1,145.51		2,121.67	1,589.15	
Other Expenses	757.36	745.82		568.63		1,325.99	1,098.66	
EBITDA	2,434.53	1,135.39	114%	2,124.89	15%	4,559.42	2,405.97	90%
EBITDA Margin (%)	28%	20%		29%		28%	22%	
Other Income	28.13	121.46		154.39		182.52	160.85	
Depreciation	660.22	568.38		654.24		1,314.46	1,125.61	
Finance Cost	200.40	152.68		166.97		367.37	366.94	
Profit before Tax	1,602.04	535.79	199%	1,458.07	10%	3,060.11	1,074.27	185%
Profit before Tax(%)	18%	9%		20%		19%	10%	
Tax	471.35	81.81		429.58		900.93	153.16	
Profit After Tax	1,130.69	453.98	149%	1,028.49	10%	2,159.18	921.11	134%
PAT Margin (%)	13%	8%		14%		13%	8%	
Basic EPS (As per Profit after Tax)	5.08	2.03		4.62		9.70	4.14	

Q2 & H1FY27 – Consolidated Balance Sheet

Particulars (INR in Lakhs)	Sept 26	Mar 26
ASSETS		
Non-Current Assets		
Property, Plant and Equipment	32,089.98	31,905.90
Capital work-in-progress	576.76	396.53
Other Intangible Assets	1,268.32	742.70
Non Current Financial Assets	30.06	30.06
Other Non Current assets	1,548.78	979.90
Total Non - Current Assets	35,513.90	34,055.09
Current Assets		
Inventories	9,720.52	7,004.14
Current Financial Assets		
(i) Trade Receivables	3,940.87	5,008.33
(ii) Cash and Cash Equivalents	4.78	4.21
(iii) Bank balance	21.75	21.75
Current tax asset (net)	2,371.11	2,007.42
Total Current Assets	16,059.03	14,045.85
Total Assets	51,572.93	48,100.94

Particulars (INR in Lakhs)	Sept-26	Mar-26
Equity		
Equity Share Capital	2,224.99	2,224.99
Other Equity	32,374.12	30,220.26
Total Equity	34,599.11	32,445.25
Liabilities		
Non-Current Liabilities		
Financial Liabilities		
(i) Borrowings	3,301.14	3,135.30
Deferred Tax Liabilities (net)	1,392.57	1,285.82
Provisions, Non current Liabilities	288.25	280.84
Total Non-Current Liabilities	4,981.96	4,701.96
Current Liabilities		
Financial liabilities		
(i) Borrowings	1,300.98	2,395.09
(ii) Trade Payables	6,225.06	5,154.00
(iii) Other Current Financial Liabilities	1,613.00	1,523.00
Other Current Liabilities	1,969.77	1,017.45
Current Tax Liabilities (Net)	883.05	864.19
Total Current Liabilities	11,991.86	10,953.73
Total Equity and Liabilities	51,572.93	48,100.94

Q2 & H1FY27 – Consolidated Cash Flow Statement

Cash Flow Statement (INR in Lakhs)	H1FY27	H1FY26
Profit before Tax	3,060.11	1,074.27
Operating Profit before Working Capital Changes	4,676.45	2,552.98
Changes in Working Capital	-2,178.86	784.26
Cash Generated from Operations	2,497.59	3,337.24
Less: Direct Taxes paid	-151.95	-278.53
Net Cash from Operating Activities	2,345.64	3,058.71
Cash Flow from Investing Activities	-2,204.39	-2,739.95
Cash Flow from Financing Activities	-140.68	-328.08
Net increase/ (decrease) in Cash & Cash equivalent	0.57	-9.32
Add: Cash and cash equivalents as at beginning of the period	4.21	10.16
Cash and cash equivalents as at end of the period	4.78	0.84

Company Overview

The background of the slide is a photograph of a laboratory. In the foreground, a person wearing a white lab coat, safety goggles, and gloves is holding a red vial. In the background, other people in lab coats are working. The image is overlaid with a blue and red color scheme and a hexagonal pattern of white lines and dots at the bottom.

From Vision to Value: Sakar Healthcare at a Glance

- Founded by **Mr. Sanjay Shah**, Sakar Healthcare has evolved from a contract manufacturer into an **API-integrated pharmaceutical organization** with a strong presence across **oral solids, injectables, and oncology formulations**.
- Over two decades, the company has built a reputation for **credibility, compliance, and precision**, supported by world-class **WHO and EU-GMP certified facilities** in Gujarat and a global network of partnerships across regulated markets.
- The establishment of a **state-of-the-art oncology facility at Bavla**, equipped with integrated **API and FDF capabilities**, marks a defining milestone in Sakar's transformation. This expansion elevates the company from a reliable formulation partner to a **vertically integrated player** in the global oncology space — combining **scientific innovation, scalable manufacturing, and sustainable operations**.
- As it enters its next phase of growth, Sakar Healthcare stands positioned for **onco-led value creation**, leveraging its legacy of quality and research excellence to deliver **specialized, high-compliance healthcare solutions worldwide**.



292+

Product Registrations
MAAs



300+

Dossiers filed (in
process)



75+

International Partners
Network



60+

Country Presence
(Emerging Markets)



25+

Therapeutic Segments
Coverage



55

Oncology Molecules
Development to Launch

Board of Directors

Sanjay Shah **Promoter, Chairman & Managing Director**

Founder-promoter with over decades of cross-industry experience, leading the Company's strategy, operations, and growth initiatives.

Visalakshi Chandramouli **Non-Executive Director**

Provides independent oversight and strategic guidance at the board level.

Megha Samdani **Independent Director**

Company Secretary with expertise in mergers, capital raising, and financial restructuring.

Aarsh Shah **Promoter, Joint Managing Director**

Pharmacist and UK-educated MBA spearheading production, international sales, and global customer relationships.

Jignesh Parikh **Independent Director**

HVAC expert with extensive experience in pharmaceutical manufacturing facilities including Onco, Hormonal, and Beta plants.

Hiral Patel **Independent Director**

MBA (Finance) with over seven years of experience across finance, banking, taxation, and legal domains.

Sunil Marathe **Whole-time Director – Technical**

Technical professional with a Master's degree in Organic Chemistry and 30+ years of industry experience, supporting manufacturing and quality operations.

Khyati Shah **Independent Director**

Company Secretary and legal professional with over five years of experience in finance, secretarial, and compliance matters.

Reeya Kothari **Independent Director**

Company Secretary with hands-on experience in taxation, legal, and secretarial functions

Leadership Team that Drives Growth



HIGH POTENT ONCOLOGY OSD (Tablet, Capsule, Granule)
HIGH POTENT ONCOLOGY INJECTION (Liquid, Lyophilised)
GENERAL SMALL VOLUME PARENTERAL (Liquid, Lyophilised)

Sakar is at crux of next phase of growth, prepared to enter the niche segment of Oncology to cater to humanity. Sakar is well equipped to deliver High Precision Research works, suitably followed by Technology Transfer and Scale-up to commercialize Anti-Cancer products worldwide."



Mr. Sanjay Shah
Chairman & MD



Mr. Aarsh Shah
JT. MD



Mr. Sunil Marathe
Technical Director



Mr. Dharmesh Thaker
CFO



Mr. Bikramjit Ghosh
VP-Strategy & Business
Development

Vision

To become a global healthcare organization based on three pillars- people, partnership and performance; making lives healthy happy and more meaningful by providing world class healthcare solutions.



Mission

To strengthen our core competencies to become the preferred choice in existing partnerships and explore new market opportunities to expand range of products and services- respecting laws, protecting environment and benefitting mankind




Values

Committed team

Loyal to partners

Focused on results

Innovative approach



Diversified Model

Sakar Healthcare operates a diversified business model comprising **CDMO Services, Own Brand Exports and Product Development Technology Transfer** enabling a balance between stability and strategic growth.

CDMO / CMO Services


Sakar Healthcare provides **Contract Development and Manufacturing (CDMO/CMO)** services to leading multinational and domestic pharmaceutical companies. The company's integrated setup enables product development, scale-up, and regulatory dossier support under global compliance standards. This vertical ensures consistent capacity utilization and steady recurring revenues.

Own Brand Exports – The Growth Driver

Sakar markets its own branded formulations across **60+ countries**, building brand equity and higher-margin revenue streams. The company's global footprint spans **APAC, Latin America, Africa, CIS, and Europe**, positioning it as a preferred partner in both branded and generic markets.

Licensing / Product Development

Sakar Healthcare co-develops product under **patent non-infringing** set and **effect Technology Transfer** or scale up to commercial batches based on partner requirements. Sakar License out developed CTD dossiers.



A Differentiated Solutions Provider



Platform Integration

EU-GMP certified oncology FDF facility with integrated API

Ready EU CTD dossiers with 22 global Marketing Authorizations granted

First patent received; APIs developed with 16 written regulatory confirmation



Profitability & Partnerships

Diversified model: LSA, CDMO, CRAMS, tech transfer, profit sharing

Oncology delivers ~2x higher margins vs. general formulations

Shift towards own brand exports (70%) enhancing profitability



Pipeline Strength

55 oncology molecules developed; 32 dossiers ready for launch

Developing Liposomal (Doxorubicin) & HME products (Apalutamide, Olaparib, Enzalutamide)

Focused on development of non-infringing patent formulations for regulated markets



Purpose & Technology

Advanced Flow Chemistry (Vapourtech, UK) and GEA granulation lines

Toffolo lyophilizes, Di-Dietrich glass reactors ensure global compliance

Green Chemistry, ZLD & solar systems driving sustainable manufacturing



Trusted by Pharma Leaders



ZYDUS LIFESCIENCES LIMITED



TORRENT PHARMACEUTICALS LTD.



HEUMANN PHARMA



MERCK LIMITED



INTAS PHARMACEUTICALS LTD.



ACCORD HEALTHCARE LTD.



EMCURE PHARMACEUTICALS LIMITED



TILLOMED LABORATORIES LTD.



ABBOTT INDIA LTD.



INDOCO REMEDIES LIMITED



USV LTD.



CADILA PHARMACEUTICALS LTD.



BAXTER



PHAROS PHARMACEUTICAL



STRIDES ARCOLAB LIMITED



CIPLA LIMITED.



IPCA LABORATORIES LTD.



WOCKHARDT LTD.




GLENMARK PHARMACEUTICALS LIMITED



FERRING PHARMACEUTICALS

Our Long-Standing Client Association



Oncology – The Future with Sakar

Oncology – the driving growth engine

Oncology lies at the core of Sakar Healthcare’s transformation. As the global cancer burden continues to rise, the need for safer, more accessible, and effective therapies has never been greater.

With the growing prominence of biologics, cytotoxic, and complex generics, oncology presents one of the most compelling opportunities in pharmaceuticals—defined by high entry barriers, limited competition, and superior profitability.

For Sakar, entering the oncology space is not merely a business expansion—it represents a deliberate shift toward value-driven innovation and scientific purpose. Our EU-GMP approved Bavla facility, equipped with integrated API and FDF capabilities and advanced flow chemistry systems, enables seamless progression from research to commercialization under one roof.

Oncology in Indian Pharmaceutical landscape


Rising cancer incidence - Cancer already causes more than 26,000 deaths every day, with an estimated 20.6 million new cases and nearly 10 million deaths annually,

CAGR- The global oncology drugs market size was valued at USD 256.46 billion in 2025. The market is projected to grow to USD 697.59 billion by 2034.


Government support for oncology research is strengthening through increased funding, clinical research programmes

Market growth is accelerating, as premium therapies expand into early-stage cancer treatment, improving cure rates and reducing recurrence risk

Global Oncology Market (USD Bn)



Indian Oncology Market (USD Bn)



A research-driven, API-integrated, EU-GMP approved oncology FDF unit. Empowering global access to high-potency cancer therapies through precision research, advanced manufacturing, and sustainable innovation.

Strategic Overview



Facility:

- **Bavla, Gujarat** – EU-GMP approved, vertically integrated oncology plant
- **Product Capability:** Oral solids, oral liquids, sterile injections (liquid & lyophilised), and oncology APIs (De-Dietrich glass reactors for complex oncology molecules)
- **R&D Excellence:** Integrated F&D, ADL, and R&D labs equipped with Flow Chemistry (Vapourtec, UK)
- **Innovation Focus:** Liposomal, HME-based, and cytotoxic oral liquid formulations to enhance patient compliance and bioavailability

Portfolio Strength:



65 oncology products developed in-house
32 ready for global launch
22 Marketing Authorisations (MAs) granted in EU and worldwide

Annual Production



APIs – 12.3 MT
Oral solids – 97 million tablets, 29 million capsules
Sterile injectables – 13 million vials
Lyophilised – 22,000 vials per cycle (10 ml)

Key Differentiators

Vertically integrated from API to Finished Dosage

High containment (OEL Level 4) facility ensuring safety and compliance

Green Chemistry adoption for energy efficiency and waste reduction

Technology Transfer & Scale-Up ready labs supporting CRAMS, CDMO, & co-development models

In-house EU-CTD dossier preparation with bioequivalence studies from EMA/USFDA-approved CROs

Liquid / Lyophilised Injectable Unit - Oncology

Manufacturing Capacity (Cytotoxic injections)

Container Size	Capacity Per Hour
2ml to 10 ml	7200
20ml / 30 ml	3000

Lyophilized Product Capacity

Container Size	Capacity / Cycles
10 ml	22000 Vials



Significance of the Unit

Eurovent certified AHU

Water system-two pass RO with EDI

ETP (zero-discharge)

Manufacturing Capacity (Cytotoxic OSD)

ORAL SOLID UNIT - Oncology	Capacity
Bulk Drug	6.5-120kg/Shift
Tablet	324000 tablets/Shift
Capsule Filling	96000 capsules/Shift
Blister Packing	324000 tablets/Shift
Bottle Packing	324000 tablets/Shift



EU-GMP Approved Oncology OSD Unit

The facility meets European regulatory standards, reflecting global manufacturing compliance. Its design allows seamless scale-up from pilot to commercial batches, reducing technology transfer challenges. This ensures faster market entry and reliability in regulated supply chains.

Containment and Isolation Systems for OEL Compliance


Operations are performed in fully contained suites to safely handle high-potent APIs. The setup maintains operator and environmental protection, achieving required OEL standards upto level 4. Such containment capability differentiates Sakar as a trusted oncology manufacturer.

Fully Automatic Line with Global Machinery Integration

The plant features automated operations from granulation to final packing. Equipment sourced from GEA, Glatt, IMA, ACG, and Sejong ensures consistency and quality precision. This high degree of automation minimizes human intervention and product variability.

Oral Liquid Oncology Section with Advanced Compounding

Includes a 500L compounding vessel equipped with an in-line homogenizer and filtration system. The system supports viscous and sensitive oncology liquids, maintaining uniformity and stability. This adds flexibility to Sakar’s oncology portfolio by covering both solid and liquid dosage forms.

Oral Solids 	Injection 	APIs 	Liquid orals 
22 products developed	21 products developed	21 APIs developed	12 products developed
16 EU CTD dossiers	16 EU CTD dossiers	16 with Written Confirmation	
9 products in pipeline	9 products in pipeline	7 applied for CEP (Received approval - 2)	

- 11 Bio-study completed from EMA / US FDA approved CROs
- RLD's are from EU

Business Contracts

60+

Overseas Business contracts

25
Europe
(LSA & CMO)

44
Rest Of
World

Dossier Status

261 ▶ 351

QoQ change in dossiers shared

178 ▶ 191

QoQ change in dossiers submitted

16 ▶ 22

QoQ change in MAs granted

Domestic
Supply Partners

15

Active partners

19


API supply partners with 8
products



The background of the slide is a photograph of a laboratory. In the foreground, a scientist wearing a white lab coat, a blue face mask, and safety goggles is working. They are holding a red test tube in their gloved hand. In the background, other scientists in similar attire are working at lab benches. The scene is lit with blue and red lights, creating a high-tech, scientific atmosphere. The bottom of the slide features a decorative graphic of white hexagons and lines on a dark blue background.

Industry Overview & Growth Drivers


Global Pharmaceutical Market (In US\$ Billion)



Global pharmaceutical manufacturing is projected to grow from **USD 549 billion in 2026 to USD 882 billion by 2031** growing at a **CAGR 9.93%**

Over **USD 300 billion** invested in greenfield and brownfield capacity expansion between 2024 and early 2026 signals strong industry momentum toward a more advanced, resilient and scalable pharmaceutical manufacturing landscape.

Indian Pharmaceutical Market (US\$ billion)



India’s pharmaceutical market is projected to grow from **USD 60.3 billion in 2026 to USD 79.7 billion by 2031** growing at a **CAGR of 5.74%**.

The growth curve is underpinned by patent expiries that widen the generic pipeline, government production-linked incentives that bolster active pharmaceutical ingredient capacity, and a rapid rise in chronic diseases that ties patients to multi-year therapy plans.

Industry Growth Drivers



Ageing Population & Chronic Disease Burden

01

Over 1 in 6 people globally will be aged 60+ by 2030, driving demand for long-term care and chronic treatments.

Shift Toward Value-Based & Preventive Care

02

Increasing adoption of data analytics and personalized medicine to improve outcomes and reduce costs.

R&D and Innovation Focus

03

The rising emphasis on research and development of advanced therapies by key players operating in the market also supports market growth.

Government & Policy Support

04

Initiatives improving access, insurance coverage, and manufacturing incentives in emerging markets like India.

Growing CDMO/CRAMS Partnerships

05


The market size was valued at USD 199.27 billion in 2025 and is projected to grow to USD 419.93 billion by 2034, exhibiting a CAGR of 8.7%.

Sustainability & Green Manufacturing

06

Industry shift toward eco-friendly and zero-discharge production systems for global compliance.

Green Chemistry **12 Principles**



Vapourtec R Series System, UK	Glass Line Reactors from De-Dietrich, Italy	OSD Containment Granulation and Compression Line, GEA, Belgium	Glatt-Autocoater, Germany	Tablet Capsule Inspection Machine by Sensum, Slovenia	Sterile Manufacturing Line with Lyophiliser, Tofflon	Kevin Roll Compacter	Bulk packaging Line IMA, Germany
-------------------------------	---	--	---------------------------	---	--	----------------------	----------------------------------


Enables Green Chemistry

Adopted techniques like Flow-Chemistry (Vapourtech) - safer with small reaction volumes, low solvent-reagent, low risk of environment exposure


Containment manufacturing-lines or Isolators in place to support Green Chemistry principles

Designs and processes are in place to suit Green Chemistry objectives

Newly installed facility along with world class equipment, provides Sakar competitive edge



Key Investment Proposition



Manufacturing Prowess



Liquid / Lyophilised Injectable Unit (Vials and Ampoules)

Manufacturing Capacity (SVP)

Ampoules	1ml & 2ml	18000
	3ml	16000
	5ml	14000

Vials	2ml	18000
	5ml & 10ml	15000
	20ml & 30ml	12000



30+

No. of Products in the
Category

Manufacturing Capacity Lyophilised

Vials	10ml	22000
-------	------	-------

Significance of the Unit

Sublimation based lyophilization improves product shelf life and reconstitution quality.

Handles both liquid and lyophilized injectables under one roof

Equipped with Tofflon lyophilizer and ORABS technology – freeze drying with autoloading and unloading

HEPA filtered Class 100 environment ensures aseptic processing

Cephalosporin - Oral Solid Unit (Tablets, Capsules, Dry Syrups & Sachets)

Manufacturing Capacity

Process	Capacity (kgs/shift)
Granulation	500 Kgs/shift
Blending	1000 kgs /shift
Compression	1200000/shift
Filling	1200000/ shift
ALU- ALU packing	1200000/ shift
ALU- ALU packing	600000/shift
Dry Syrup	25000/shift



Significance of the Unit

Core hub for oral solids with wide dosage flexibility (80–1500 mg tablets, 250–500 mg capsules).

Fully automated line from granulation to packing, minimizing contamination and material loss.

Offers packaging versatility – ALU-ALU, ALU-PVC, strip & dry syrup – suited for diverse market needs.

HEPA-filtered environment with controlled storage ensure

Cephalosporin – Injectable Unit (Dry Powder)

Manufacturing Capacity

Container size	Capacity (per Hour)
250 mg	14400
500 mg	14400
1 gm / 2 gm	11500
3 gm / 5 gm	8500



18

No. of Products in the Category

Significance of the Unit

Key sterile block for antibiotic dry powder vials (250 mg to 5 g range).

Ensures aseptic integrity with HEPA-controlled environment and segregated flows.

High-speed visual inspection (15,000 vials/hour) and automated packaging ensure quality and efficiency.

Controlled storage with humidity regulation maintains product stability and compliance

Oral Liquid Unit (Syrup & Suspension)

Manufacturing Capacity

Volumes	No of bottles/ Shift
10 ml	75000
30 ml	75000
60 ml	50000
100 ml	60000
200 ml	30000



Significance of the Unit

Key sterile block for antibiotic dry powder vials (250 mg to 5 g range).


Ensures aseptic integrity with HEPA-controlled environment and segregated flows.

High-speed visual inspection (15,000 vials/hour) and automated packaging ensure quality and efficiency.


Controlled storage with humidity regulation maintains product stability and compliance

Historical Financial Highlights


Revenue from operations (INR in Lakhs)




Operating Profit (INR in Lakhs)




Consolidated PAT (INR in Lakhs)



Debt to Equity (x)



Net-worth (INR in Lakhs)





THANK YOU



For further information,
please contact:

Company :



Sakar Healthcare Limited

CIN: L24231GJ2004PLC043861

Email – info@sakarhealthcare.com
cs@sakarhealthcare.com

Investor Relations Advisors :



MUFG Intime India Private Limited

A part of MUFG Corporate Markets,
a division of MUFG Pension & Market Service

Mr. Nikunj Seth

nikunj.seth@in.mpms.mufg.com

Mr. Sejal Bhattar

sejal.bhattar@in.mpms.mufg.com

Meeting Request

Link

